12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Visonac: Phase IIb data

A double-blind, U.S. Phase IIb trial in 153 patients aged 12-35 with severe acne vulgaris showed that 4 treatments of topical Visonac followed by red light illumination given 2 weeks apart met the primary endpoint of reducing the proportion of inflammatory acne lesions from baseline to 6...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >